Salman Hussain is a panelist during the conference. He is discussing patient-focused drug development, bringing a precision medicine approach to alopecia areata, and the latest patient reported outcomes tools and biomarker studies. The roundtable discussion includes representatives from several pharmaceutical companies, a couple physicians/researchers, and patient advocacy group members.
For more inforamtion on this event, click here.
Upper Payment Limits (UPLs) explained
Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...